Arrowstreet Capital
IMMU

Arrowstreet Capital’s Immunomedics Inc IMMU Stock Holding History

Arrowstreet Capital’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-294,656
Closed -$958K – 2749
2016
Q3 		$958K Buy
+294,656
New +$824K ﹤0.01% 1083

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Arrowstreet Capital's IMMU Position: Q4 2016 in Review

Arrowstreet Capital sold out of Immunomedics Inc (IMMU) in Q4 2016, closing a stake of 294,656 shares — an estimated $958K sold.

Arrowstreet Capital first reported a position in IMMU in Q3 2016 and held it in 1 quarter. The position peaked at $958K in Q3 2016. 109 funds tracked by Wall St. Rank hold IMMU as of Q4 2016.

  • Arrowstreet Capital reported no remaining Immunomedics Inc position as of Q4 2016 after selling out during the quarter.
  • Arrowstreet Capital sold 294,656 Immunomedics Inc shares in Q4 2016, an estimated $958K.
  • Arrowstreet Capital first reported a position in Immunomedics Inc in Q3 2016 and held it in 1 quarter.
  • Arrowstreet Capital's Immunomedics Inc position peaked at $958K in Q3 2016.
  • 109 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2016.

Based on Arrowstreet Capital's 13F filing for Q4 2016, filed 15 Feb 2017.